ImmunoGen Inc.
About ImmunoGen Inc.
ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is being advanced to Phase 3 testing for FRα-positive platinum-resistant ovarian cancer, and is also in Phase 1b/2 testing in combination regimens for earlier-stage disease. The Company's ADC technology is used in three other clinical-stage ImmunoGen product candidates, in Roche's marketed product, Kadcyla®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda.
551 articles with ImmunoGen Inc.
-
ImmunoGen Announces Webcast of Presentation and Q&A at Upcoming H.C. Wainwright Global Investment Conference
5/10/2022
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Susan Altschuller, Chief Financial Officer, will present at the upcoming H.C. Wainwright Global Investment Conference.
-
ImmunoGen, which is developing Antibody-drug conjugates (ADCs) for the treatment of cancer, is on a hiring spree. The company is looking to hire for more than 200 positions by the end of 2022.
-
ImmunoGen Reports Recent Progress and First Quarter 2022 Financial Results
5/6/2022
ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, reviewed recent progress in the business and reported financial results for the quarter ended March 31, 2022.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 02, 2022
5/2/2022
ImmunoGen, Inc. announced that on April 29, 2022, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock option awards to purchase an aggregate of 729,530 shares of its common stock to sixteen new employees under the ImmunoGen, Inc.
-
ImmunoGen Announces Conference Call to Discuss Its First Quarter 2022 Operating Results
4/21/2022
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 6, 2022 to discuss its first quarter 2022 operating results.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 01, 2022
4/1/2022
ImmunoGen, Inc. announced that on March 31, 2022, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock option awards to purchase an aggregate of 218,500 shares of its common stock to three new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended.
-
ImmunoGen Announces Webcast of Panel Discussion at Upcoming Canaccord Genuity Horizons in Oncology Virtual Conference
3/31/2022
ImmunoGen, Inc. today announced that Dr. Anna Berkenblit, Chief Medical Officer, will participate in the Reshaping Ovarian Cancer panel discussion at the upcoming Canaccord Genuity Horizons in Oncology Virtual Conference. The panel is scheduled for April 14, 2022 from 8:00 – 8:50am ET.
-
ImmunoGen Submits Biologics License Application to the US Food and Drug Administration for Mirvetuximab Soravtansine in Ovarian Cancer
3/29/2022
ImmunoGen, Inc. announced that it has submitted a Biologics License Application under the accelerated approval pathway to the US Food and Drug Administration for mirvetuximab soravtansine monotherapy in patients with folate receptor alpha -high platinum-resistant ovarian cancer who have been previously treated with 1 to 3 prior systemic treatments.
-
When ImmunoGen announced top-line results from the Phase III SORAYA trial in November 2021, the primary endpoint - confirmed objective response rate - was met at 32.4%.
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
-
ImmunoGen shares inexplicably plunged 23% after the company announced positive Phase III results of its new ovarian cancer treatment.
-
ImmunoGen Presents Full Results from Positive Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at SGO Annual Meeting
3/19/2022
ImmunoGen, Inc. announced full results from the pivotal SORAYA trial evaluating the efficacy and safety of mirvetuximab soravtansine monotherapy in patients with folate receptor alpha -high platinum-resistant ovarian cancer who have been previously treated with Avastin®.
-
Healthcare giant Sanofi and cancer-focused biotech company Seagen Inc. announced an exclusive collaboration agreement to develop antibody-drug conjugates (ADCs) for cancer treatments.
-
ImmunoGen to Present Full Results from SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer at the Society of Gynecologic Oncology Annual Meeting
3/10/2022
ImmunoGen, Inc. today announced that multiple abstracts were selected for oral and poster presentations at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer to be held on March 18-21, 2022 in Phoenix, Arizona.
-
Currently, women with breast and ovarian cancers have limited treatment options. Anixa Biosciences, ImmunoGen and IMV are working to change that.
-
ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 01, 2022
3/1/2022
ImmunoGen, Inc. announced that on February 28, 2022, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock option awards to purchase an aggregate of 198,300 shares of its common stock to three new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended.
-
ImmunoGen Reports Recent Progress and 2021 Financial Results
2/25/2022
ImmunoGen Inc. today reviewed recent progress in the business and reported financial results for the quarter and year ended December 31, 2021.
-
ImmunoGen Announces a Global, Multi-Target License Agreement of its Novel Camptothecin ADC Platform to Lilly for Up to $1.7 Billion
2/15/2022
ImmunoGen Grants Lilly Exclusive Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Lilly with ImmunoGen's Novel Camptothecin Platform.
-
Shares of ImmunoGen are climbing this morning after the company announced an antibody drug conjugate (ADCs) collaboration with Eli Lilly valued at up to $1.7 billion.
-
ImmunoGen Announces Conference Call to Discuss Its 2021 Operating Results
2/10/2022
ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, February 25, 2022 to discuss its 2021 operating results.